Decorin Induces Cardiac Hypertrophy by Regulating the CaMKII/MEF-2 Signaling Pathway In Vivo

Abstract

Objective

Cardiac hypertrophy is an adaptive reaction of the heart against cardiac overloading, but continuous cardiac hypertrophy can lead to cardiac remodeling and heart failure. Cardiac hypertrophy is mostly considered reversible, and recent studies have indicated that decorin not only prevents cardiac fibrosis associated with hypertension, but also achieves therapeutic effects by blocking fibrosis-related signaling pathways. However, the mechanism of action of decorin remains unknown and unconfirmed.

Methods

We determined the degree of myocardial hypertrophy by measuring the ratios of the heart weight/body weight and left ventricular weight/body weight, histological analysis and immunohistochemistry. Western blotting was performed to detect the expression levels of CaMKII, p-CaMKII and MEF-2 in the heart.

Results

Our results confirmed that decorin can regulate the CaMKII/MEF-2 signaling pathway, with inhibition thereof being similar to that of decorin in reducing cardiac hypertrophy.

Conclusion

Taken together, the results of the present study showed that decorin induced cardiac hypertrophy by regulating the CaMKII/MEF-2 signaling pathway in vivo, revealing a new therapeutic approach for the prevention of cardiac hypertrophy.

Keywords

decorin / cardiac hypertrophy / calcium/calmodulin-dependent protein kinase II / myocyte enhancer factor 2 / atrial natriuretic peptide

References

[1] HeinekeJ, MolkentinJD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol, 2006, 7(8): 589-600

[2] CohnJN, FerrariR, SharpeN. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol, 2000, 35(3): 569-582

[3] GradmanAH, AlfayoumiF. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis, 2006, 48(5): 326-341

[4] van BerloJH, MailletM, MolkentinJD. Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest, 2013, 123(266): 37-45

[5] KoitabashiN, KassDA. Reverse remodeling in heart failure—mechanisms and therapeutic opportunities. Nat Rev Cardiol, 2011, 9(134): 147-157

[6] ManabeI, ShindoT, NagaiR. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res, 2002, 91(357): 1103-1113

[7] GabbianiG. The biology of the myofibroblast. Kidney Int, 1992, 41(206): 530-532

[8] ZeisbergM, StrutzF, MullerGA. Role of fibroblast activation in inducing interstitial fibrosis. J Nephrol, 2000, 13(99): 1121-8428

[9] GoldoniS, OwensRT, McQuillanDJ, et al.. Biologically active decorin is a monomer in solution. J Biol Chem, 2004, 279(86): 6606-6612

[10] YanW, WangPC, TangJ, et al.. Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factorbeta/Smad and p38 mitogen-activated protein kinase signaling pathways. Human Gene Therapy, 2009, 20(51): 1190-1200

[11] KudohS, AkazawaH, TakanoH, et al.. Stretch-modulation of second messengers: effects on cardiomyocyte ion transport. Prog Biophys Mol Biol, 2003, 82(29): 57-66

[12] ZhangT, KohlhaasM, BacksJ, et al.. CaMKIIdelta isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. J Biol Chem, 2007, 282(149): 35078-35087

[13] Abdel-WahabN, WicksSJ, MasonRM, et al.. Decorin suppresses transforming growth factor-beta-induced expression of plasminogen activator inhibitor-1 in human mesangial cells through a mechanism that involves Ca2+-dependent phosphorylation of Smad2 at serine-240. Biochem J, 2002, 362(60): 643-649

[14] WangT, HouLB, LiuZJ, et al.. Intramuscular delivery of rAAV-mediated kallikrein gene reduces hypertension and prevents cardiovascular injuries in model rats. Acta Pharmacol Sin, 2007, 28(6): 1898-1906

[15] SatoK, SuematsuA, NakashimaT, et al.. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat Med, 2006, 12(236): 1410-1416

[16] KompaAR, SeeF, LewisDA, et al.. Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction. J Pharmacol Exp Ther, 2008, 325(46): 741-750

[17] DunkmanAA, BuckleyMR, MienaltowskiMJ, et al.. Decorin expression is important for age-related changes in tendon structure and mechanical properties. Matrix Biol, 2013, 32(103): 3-13

[18] DunkmanAA, BuckleyMR, MienaltowskiMJ, et al.. The injury response of aged tendons in the absence of biglycan and decorin. Matrix Biol, 2014, 35(44): 232-238

[19] SchaeferL, TredupC, GubbiottiMA, et al.. Proteoglycan neofunctions: regulation of inflammation and autophagy in cancer biology. Febs j, 2017, 284(78): 10-26

[20] HorvathZ, KovalszkyI, FullarA, et al.. Decorin deficiency promotes hepatic carcinogenesis. Matrix Biol, 2014, 35(50): 194-205

[21] DuncanMB. Extracellular matrix transcriptome dynamics in hepatocellular carcinoma. Matrix Biol, 2013, 32(17): 393-398

[22] PatelS, SantraM, McQuillanDJ, et al.. Decorin activates the epidermal growth factor receptor and elevates cytosolic Ca2+ in A431 carcinoma cells. J Biol Chem, 1998, 273(102): 3121-3124

[23] WuZ, HorganCE, CarrO, et al.. Biglycan and decorin differentially regulate signaling in the fetal membranes. Matrix Biol, 2014, 35(26): 266-275

[24] BaghyK, IozzoRV, KovalszkyI. Decorin-TGFbeta axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem, 2012, 60(99): 262-268

[25] JarvelainenH, SainioA, WightTN. Pivotal role for decorin in angiogenesis. Matrix Biol, 2015, 43(77): 15-26

[26] BrandanE, GutierrezJ. Role of skeletal muscle proteoglycans during myogenesis. Matrix Biol, 2013, 32(45): 289-297

[27] Barallobre-BarreiroJ, GuptaSK, ZoccaratoA, et al.. Glycoproteomics Reveals Decorin Peptides With Anti-Myostatin Activity in Human Atrial Fibrillation. Circulation, 2016, 134(26): 817-832

[28] GronauT, KrugerK, PreinC, et al.. Forced exercise-induced osteoarthritis is attenuated in mice lacking the small leucine-rich proteoglycan decorin. Ann Rheum Dis, 2017, 76(19): 442-449

[29] MerlineR, LazaroskiS, BabelovaA, et al.. Decorin deficiency in diabetic mice: aggravation of nephropathy due to overexpression of profibrotic factors, enhanced apoptosis and mononuclear cell infiltration. J Physiol Pharmacol, 2009, 60(59): 5-13

[30] IozzoRV, BuraschiS, GenuaM, et al.. Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem, 2011, 286(98): 34712-34721

[31] MorcavalloA, BuraschiS, XuSQ, et al.. Decorin differentially modulates the activity of insulin receptor isoform A ligands. Matrix Biol, 2014, 35(35): 82-90

[32] SeidlerDG, MohamedNA, BocianC, et al.. The role for decorin in delayed-type hypersensitivity. J Immunol, 2011, 187(40): 6108-6119

[33] LehmannLH, WorstBC, StanmoreDA, et al.. Histone deacetylase signaling in cardioprotection. Cell Mol Life Sci, 2014, 71(30): 1673-1690

[34] KimY, PhanD, van RooijE, et al.. The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. J Clin Invest, 2008, 118(159): 124-132